June 4, 2009 — The latest results from the European First Episode Schizophrenia Trial (EUFEST) show that when it comes to improving cognition in patients with schizophrenia, there is little difference ...

Clozapine significantly improves survival rates in patients with treatment-resistant schizophrenia compared with other second-generation antipsychotics, according to a study that suggests wider use of ...

Cobenfy represents a breakthrough schizophrenia treatment with a novel mechanism, but limited long-term data requires ...

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class ...

While tardive dyskinesia is most often caused by sustained exposure to antipsychotics, any drug that significantly blocks dopamine receptors can be a culprit, said Demian Rose, MD, PhD, of the ...

Schizophrenia is currently treated with older medications with limited efficacy and troublesome side effects that lead many patients to stop taking them. The FDA has approved a novel Bristol Myers ...

The approval of medicines called second-generation antipsychotics has allowed bipolar I and other associated conditions to be treated. A person with bipolar I disorder can go through various mood ...

In a review of studies involving children and adolescents taking antipsychotics, a new systematic literature review found rates of TD between 5% and 20%. Risk factors for TD in this population include ...

The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...

Credit: Getty Images This patient fact sheet describes the medications that are known to induce tardive dyskinesia, its symptoms, and ways in which the disease state may be managed. Our easy-to-read ...